Valuation: Protara Therapeutics, Inc.

Market Cap 194M 170M 161M 146M 274M 18.58B 276M 1.92B 745M 9.49B 728M 712M 30.5B P/E 2026 *
-2.36x
P/E 2027 * -2.14x
Enterprise Value 194M 170M 161M 146M 274M 18.58B 276M 1.92B 745M 9.49B 728M 712M 30.5B EV / Sales 2026 *
-
EV / Sales 2027 * 194x
Free-Float
97.7%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Protara Therapeutics, Inc.

1 day-2.09%
1 week-7.61%
Current month-15.03%
1 month-17.38%
3 months-18.00%
6 months-38.23%
Current year-38.46%
1 week 3.23
Extreme 3.23
3.88
1 month 3.23
Extreme 3.23
4.04
Current year 3.23
Extreme 3.23
7.5
1 year 3.23
Extreme 3.23
7.82
3 years 1.04
Extreme 1.04
10.48
5 years 1.04
Extreme 1.04
10.48
10 years 1.04
Extreme 1.04
67.08
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 45 01/03/2019
Chief Executive Officer 54 01/11/2017
Director of Finance/CFO 58 30/01/2023
Director TitleAgeSince
Chairman 67 01/01/2020
Director/Board Member 68 01/01/2020
Director/Board Member 60 01/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
30/06/26 Don

Founder

-30,000 0.0534%
15/06/26 Free

Director

31,000 0.0552%
15/06/26 Free

Director

31,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
-2.09%-7.61%-23.54%+100.00% 194M
-3.30%+1.50%+51.24%+99.26% 72.26B
+1.25%-3.01%+40.12%+77.12% 60.24B
+2.12%+5.26%+32.50%+21.28% 27.73B
-3.06%-1.81%-13.10%+357.06% 25.74B
-0.75%+2.56%+0.45%-4.46% 24.75B
+0.40%+0.75%+22.91%-9.68% 20.74B
-1.70%-2.12%+146.86%+314.52% 15.06B
+0.36%-0.34%+50.32%+166.42% 14.42B
+0.21%+1.17%-8.07%+499.10% 14.23B
Average -0.66%-0.37%+29.97%+162.06% 27.54B
Weighted average by Cap. -0.77%+0.30%+36.27%+129.09%

Financials

2026 *2027 *
Net sales - 1M 878K 829K 755K 1.41M 95.84M 1.42M 9.92M 3.84M 48.96M 3.75M 3.67M 157M
Net income -85.87M -75.35M -71.16M -64.85M -121M -8.23B -122M -852M -330M -4.2B -322M -315M -13.51B -108M -94.63M -89.37M -81.44M -152M -10.34B -154M -1.07B -414M -5.28B -405M -396M -16.97B
Net Debt - -
Logo Protara Therapeutics, Inc.
Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing transformative therapies for people with cancer and rare diseases. The Company's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin, as well as a Phase II trial in pediatric patients with LMs. TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes. Additionally, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes.
Employees
46
Date Price Change Volume
25/09/26 $3.280 -2.09% 552,942
24/09/26 $3.350 -5.37% 661,970
23/09/26 $3.540 -3.80% 882,844
22/09/26 $3.680 +4.84% 2,893,290
21/09/26 $3.510 -1.13% 735,465
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.280USD
Average target price
25.71USD
Spread / Average Target
+683.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TARA Stock